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Abstract
Background: Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in
ophthalmological clinical research. However, to date only little information is available about vrQoL from large non-
interventional studies in terms of "real-world evidence". The purpose of this investigation was to describe baseline
VFQ-25 visual function scores, to evaluate whether they differ from previous phase III clinical trials, to determine
which contributing factors (e.g. indication, age, gender) affect VFQ-25 scores and to identify its impact on driving.
Methods: The non-interventional OCEAN study (Observation of treatment patterns with LuCEntis and real life ophthalmic
monitoring, including optional OCT in Approved iNdications) is the largest ophthalmic study conducted in Germany, to
evaluate the real world situation of patients treated with ranibizumab (NCT02194803). The NEI-VFQ-25 questionnaire was
conducted at baseline, months 4, 12 and 24. Descriptive statistics was used to analyse the baseline data. ANOVA was
performed to evaluate the impact of various contributing factors on composite and selected subscale scores.
Results: Overall, 4844 (84.1 %) of all 5760 OCEAN patients completed the VFQ-25 questionnaire at baseline. Thereof, 3414
treatment-naïve patients were further analysed. Overall, the VFQ subscore general health was most affected by the ocular
disease, followed by general vision. No major differences were detected in comparison to corresponding VFQ-25 scores of
previous phase III clinical trials, except in DME patients, or with respect to possible contributing factors. A tendency
towards a more decreased VFQ-25 composite score was observed for nAMD, for elderly patients ≥75 years of age, for
female patients, for patients with low baseline visual acuity (VA; <50 letters) and for those with statutory health insurance.
Indication, age, gender, baseline VA (all p <0.01) and the interaction of age and indication, as well as baseline VA and
indication (p <0.01 each) had a significant impact on composite, general vision and distance vision scores (ANOVA). About
10 % of patients gave up driving due to eyesight issues.
Conclusions: The knowledge of a patient’s subjective disease burden is crucial to understanding anxieties and mental
anguish. Additionally, the understanding of the impact of various contributing factors on the
VFQ-25 scores and the extent to which they can be influenced help to optimize patient care. It demonstrates the need
for medical and mental support by all medical staff, to encourage patients’ compliance with a comprehensive anti-VEGF
therapy, to increase BCVA and, consecutively, VFQ-25 scores.
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Background
In the last decades, major improvements have been made
in ophthalmology to objectively assess patients’ impair-
ment due to ocular diseases and to quantify the outcome
of various interventions [1]. Besides merely determining
visual acuity (VA), which was the gold standard in the
past, the additional evaluation of patients’ health-related
quality of life (QoL) has come to the fore and is broadly
implemented nowadays [2, 3]. The National Eye Institute
(NEI) Visual Function Questionnaire (VFQ)-25 is a well-
established and validated survey to objectively evaluate
patients’ disease burden, to determine vision-related QoL
[1, 4, 5] and the psychometric properties of diseases that
cause vision loss, like glaucoma [6, 7], cataract [8] and
Graves’ ophthalmopathy [9], amongst others [10–14].
Furthermore, it allows an objective judgement of the effect
of different interventions like intraocular lens (IOL)
implantations [8] or intravitreal anti-vascular endothelial
growth factor (VEGF) injections [15–17] on QoL. Hence,
the NEI VFQ-25 has been used in almost all phase III
trials evaluating the efficacy and safety of intravitreally
administered ranibizumab in different indications to ob-
jectively determine QoL and, thus, the disease burden for
each participating patient [15–17]. QoL measurements
are now an integral part of health utility analyses and the
drug pricing process in certain countries [18].
The ongoing OCEAN study (Observation of treatment
patterns with LuCEntis and real life ophthalmic monitor-
ing, including optional OCT in Approved iNdications), at
present the largest German observational study in ophthal-
mology, was initiated to evaluate the treatment patterns
with intravitreally injected ranibizumab in real-world
clinical care for all approved indications (neovascular age-
related macular degeneration [nAMD], diabetic macular
edema [DME], macular edema due to retinal vein occlu-
sion [RVO; central RVO [CRVO] or branch RVO [BRVO]]
and myopic chorioretinal neovascularization [mCNV]).
A patient’s current QoL and individual burden of dis-
ease is of special interest for all medical staff involved, to
optimize not only medical treatment but also emotional
attention, both of which directly impact QoL [3]. While
phase III, controlled clinical trials generally enroll
healthier, strictly selected patients [19], the QoL of real-
world patients may be influenced more strongly by con-
tributing factors (e.g. indication, age, gender).
The scope of this report was to evaluate the baseline QoL
and disease burden of patients scheduled for intraocular
ranibizumab treatment due to various neovascular eye
disorders in routine clinical care. The baseline VFQ-25
scores from OCEAN were compared with corresponding
results of previous phase III clinical trials, to assess which
contributing factors instantly affect QoL and to identify
QoL’s impact on driving. Identifying and addressing such
factors, if possible, will help to increase overall QoL.
Methods
The OCEAN study is an open-label, prospective, multi-
centre, non-interventional study (NIS). Its aim is to
observe treatment patterns of intravitreal ranibizumab
injections for a period of up to 24 months per patient,
including an optional retrospective documentation of
any prior anti-VEGF treatment. Recruitment ended in
December 2014. The NEI-VFQ-25 questionnaire was
administered at baseline, and is repeated at months 4, 12
and 24. The questionnaire covers general health, quality of
vision (general vision, near vision, distance vision, periph-
eral vision, colour vision) and vision-related QoL (driving,
ocular pain, role limitations, dependency, social function
and mental health). Scores range from 0 (maximally
compromised) to 100 (not compromised) [4, 5, 20]. For this
report, the baseline VFQ-25 scores and subscale scores
were evaluated. The NIS OCEAN was conducted in
accordance with the German Drug Law and was approved
by the respective Ethics Committee prior to study initiation.
All procedures adhered to the ethical standards of the re-
sponsible committee as well as the declaration of Helsinki.
Written informed consent was obtained from all patients
following an explicit explanation of the aim of the study.
All participating physicians received compensation for the
documentation of each patient in accordance with the offi-
cial scale of physicians’ fees (http://www.bmg.bund.de/glos-
sarbegriffe/g/gebuehrenordnung-fuer-aerzte-und-zahnaerz-
te.html). All decisions regarding procedures and treatments
were made by the physicians and were not influenced; the
frequency and scope of all examinations were to reflect rou-
tine clinical practice.
The statistical analysis was conducted according to a
predefined statistical analysis plan. The descriptive statistics
was performed to identify any variables with predictive
validity. Results were also displayed according to
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appropriate strata. The documented data were examined
for plausibility before analysis. An analysis of variance
(ANOVA) was performed based on iterative backward
selection.
Results
Overall, 4844 (84.1 %) of all 5760 OCEAN patients were
included in the VFQ analysis set, thereof 2096 (43.3 %)
male and 2732 (56.4 %) female participants. In 16 cases
(0.3 %), gender was not documented. Overall mean age (±
standard deviation [SD]) was 74.7 ± 10.4 years (median
[1st/3rd quartile]: 76.1 years [69.7/81.8]). Information on
age was missing for 19 patients (0.4 %). Only 434 (9.0 %)
patients were covered by a private health insurance, while
4386 (90.5 %) patients had statutory health insurance
(missing data for 24 patients [0.5 %]).
With respect to pre-treatment status, 3414 (70.5 %)
patients were classified as treatment-naïve (but with
variability regarding the time of diagnosis), 741 (15.3 %) as
pre-treated (i.e. patients with prior documented treatment
with ranibizumab or any other anti-VEGF-treatment) and
689 (14.2 %) as possibly pre-treated (all other patients).
Concerning indications, 3118 (64.4 %) participants had
been diagnosed with nAMD, 1033 (21.3 %) with DME,
659 (13.6 %) with RVO, thereof 195 (29.6 %)/113 (17.2 %)
with BRVO/CRVO (missing sub-diagnosis for 351 patients
[53.3 %]) and 34 (0.7 %) with mCNV.
The overall VFQ-25 composite scores at the OCEAN
baseline visit are displayed in Table 1 and Fig. 1. Overall
VFQ-25 subscale scores (all indications) are demon-
strated in Table 2 and Fig. 1. Overall, general health,
general vision and driving seem to be most affected in
the OCEAN patients. In contrast, ocular pain and colour
vision are least affected, followed by vision-specific social
function, vision-specific dependency and peripheral vi-
sion. When comparing treatment-naïve and pre-treated
patients, the pre-treated patients tend to show more de-
creased scores for distance vision, vision-specific role
limitations and driving.
All further analyses presented in this report focus on
the treatment-naïve patients, because the baseline VFQ-
25 scores of naïve patients represent a more precisely
defined and homogeneous group.
Figure 2a presents the differences in baseline VFQ-25
scores by indication (nAMD/DME/RVO [BRVO/
CRVO]) in treatment-naïve patients. The analysis in-
cluded 2264 patients (66.3 %) with nAMD, 655 (19.2 %)
with DME, 139 (4.1 %) with BRVO, and 80 (2.3 %) with
CRVO (missing RVO classification in 253 patients
(7.4 %)). The mCNV patients are not analysed in detail
here, as this population is too small to allow reliable
conclusions. Patients suffering from RVO of any type
tend to show the highest VFQ-25 scores, followed by
DME and nAMD patients. The most decreased visual
function is detected for nAMD patients, with signifi-
cantly worse results (non-overlapping 95 % confidence
intervals) in the composite score and in several subscale
scores (general vision, near vision, distance vision, and
the vision-specific scores social function, mental health,
role limitations and dependency) compared to the other
indications. Overall, however, no major differences
between the indications can be observed.
The differences in baseline VFQ-25 scores by age are
displayed in Fig. 2b. Among all treatment-naïve patients,
528 (15.5 %) are younger than 65 years and, thus, of
working age. A total of 943 (27.6 %) participants are be-
tween 65 and 75 years of age (early retirement phase)
and the majority (1928 [56.5 %] patients) are 75 years
and older. There is a tendency towards a decrease in
visual function with increasing age. In comparison to
both younger age groups, the composite score and all
subscale scores are significantly more affected for
patients aged 75 years and older (non-overlapping 95 %
confidence intervals).
The baseline VFQ-25 scores by gender are shown in
Fig. 2c. A total of 1496 (43.8 %) treatment-naïve partici-
pants are male and 1904 (55.8 %) are female (missing
gender in 14 cases [0.4 %]). No major differences
between genders are detected. A tendency towards a
more decreased visual function for females is observed,
as significantly reflected in the composite score and
most subscale scores (non-overlapping 95 % confidence
intervals), except for colour vision.
Variations in baseline VFQ-25 scores in treatment-
naïve patients dependent on the baseline best-corrected
VA (BCVA) of the treated eye at baseline are shown in
Fig. 2d. A total of 915 participants (26.8 %) have a BCVA
of less than 50 letters, 1065 (31.2 %) of 50 to 65 letters
and 1404 (41.1 %) of more than 65 letters. There is a
tendency towards a more decreased visual function for
patients with lower baseline BCVA, which is significantly
reflected in the composite score and most subscale
scores except for general health and ocular pain (non-
overlapping 95 % confidence intervals).
The baseline VFQ-25 scores of treatment-naïve
patients by health insurance type are displayed in Fig. 2e.
A total of 323 patients (9.5 %) are covered by private
health insurance and 3072 (90.0 %) by statutory health
insurance (missing data for 19 [0.6 %] patients). Overall,
Table 1 Baseline VFQ-25 composite scores of all OCEAN patients
as well as stratified data of treatment-naïve and pre-treated patients







Composite score 74.0 [73.5; 74.6] 75.0 [74.3; 75.6] 71.4 [69.8; 72.9]
aMissing data for <2 % in composite score
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no major differences are visible between the health
insurance types. There is a tendency towards a more
decreased visual function for statutorily insured patients,
as significantly demonstrated by a decreased composite
score and several subscale scores (near vision, distance
vision, peripheral vision and the vision-specific scores
social function, mental health and dependency (non-
overlapping 95 % confidence intervals).
The above comparisons of baseline VFQ-25 scores
are based on the single parameters indication, age,
gender, baseline BCVA and health insurance type. An
additional ANOVA including all these parameters (ex-
cept health insurance type), as well as their pairwise
interactions was performed for the composite score
and for the subscale scores general vision and dis-
tance vision. Statistical significance could be shown
for all single parameters (all p <0.01), for the inter-
action of age and indication (p <0.01), as well as for
the interaction of baseline BCVA and indication (p
<0.01). Results are comparable for the three analysed
VFQ-25 scores.
Figure 3a presents driving licences, vehicle registra-
tions and driven kilometres in Germany by age [21, 22].
Table 3 and Fig. 3b to e show the age distributions of
the OCEAN participants who gave up driving generally
or mainly due to eyesight issues, by indication. In
Germany the maximum of driving licences, vehicle reg-
istrations and driven kilometres can be found in the age
class between 40 and 45 years, decreasing constantly in
the older age classes with a distinct reduction from
65 years on. In the OCEAN study, the number of
patients who gave up driving generally increases from
between 50 and 60 years of age onwards, reaching a
maximum in the age classes between 80 and 100. The
leading cause for giving up driving is mainly eyesight.
This is generally most pronounced for nAMD patients,
followed by DME, BRVO and CRVO.
Fig. 1 Histogram of vision subscales with mean and confidence interval for all indications evaluated
Table 2 Overall VFQ-25 subscale scores (all indications) as well
as stratified data of treatment-naïve and pre-treated patients







General health 45.3 [44.7; 45.8] 45.9 [45.3; 46.6] 43.8 [42.4; 45.3]
General vision 59.5 [59.0; 60.0] 59.7 [59.1; 60.3] 58.8 [57.4; 60.1]
Ocular pain 86.5 [85.9; 87.0] 87.2 [86.6; 87.8] 85.8 [84.4; 87.1]
Near vision 67.0 [66.2; 67.7] 67.8 [67.0; 68.7] 64.1 [62.2; 66.1]
Distance vision 70.7 [69.9; 71.4] 71.9 [71.0; 72.7] 66.2 [64.2; 68.3]
Social function
(vision specific)
83.8 [83.1; 84.5] 84.9 [84.1; 85.7] 81.4 [79.5; 83.2]
Mental health
(vision specific)
67.9 [67.3; 68.6] 68.8 [68.0; 69.5] 65.1 [63.3; 67.0]
Role limitations
(vision specific)
69.2 [68.4; 70.1] 70.5 [69.4; 71.5] 64.6 [62.2; 67.0]
Dependency
(vision specific)
82.1 [81.3; 82.9] 83.3 [82.4; 84.2] 79.8 [77.6; 81.9]
Driving 59.6 [58.3; 60.9] 60.0 [58.5; 61.6] 54.1 [50.5; 57.6]
Colour vision 89.6 [89.0; 90.2] 90.3 [89.6; 91.0] 89.1 [87.5; 90.6]
Peripheral vision 74.9 [74.1; 75.6] 76.2 [75.3; 77.1] 71.2 [69.2; 73.2]
aMissing data for <3 % in subscale scores; except for driving, which is only
reported for those subjects who reported to currently drive or to have given
up driving mainly due to eyesight
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Overall, the mean BCVA (± SD) of the treated eye is 58.4 ±
18.3 letters in patients driving at study baseline. The BCVA is
lower in patients who gave up driving mainly due to eyesight
issues (47.4 letters ± 20.7), who gave up driving mainly due to
other reasons (55.1 letters ± 20.0) and who gave up driving
due to eyesight and other reasons (48.6 letters ± 23.1).
Discussion
Being aware of a patient’s subjective QoL and disease
burden, as objectively evaluated using the NEI VFQ-25,
is crucial to understand a patient’s anxieties, to encour-
age compliance with initiated intravitreal anti-VEGF
therapy and regular monitoring, as well as to support
Fig. 2 a Differences in baseline VFQ-25 scores by indication (nAMD/DME/RVO). b Differences in baseline VFQ-25 scores by age. c Baseline VFQ-25
scores by gender. d Variations in baseline VFQ-25 scores in treatment-naïve patients dependent on baseline BCVA. e Baseline VFQ-25 scores of
treatment-naïve patients by health insurance type
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the physician’s and staff ’s empathy. Furthermore, know-
ing the impact of different contributing factors to QoL
scores allows the medical staff to estimate whether QoL
can be influenced by the medical therapy itself or by
supporting emotional attention [3]. For example, if age
or gender had a major impact on QoL, these factors
would be non-modifiable. On the other hand, if VA was
found to be a key factor for QoL scores, there would be
Fig. 3 a Driving licences, vehicle registrations and driven kilometres in Germany by age. b–e Age distribution of OCEAN participants who gave
up driving generally or mainly due to eyesight issues, by indication
Bertelmann et al. Health and Quality of Life Outcomes  (2016) 14:132 Page 6 of 11
a good chance to improve these scores by adequate
medical treatment and emotional attention.
The NEI-VFQ-25 measures the influence of visual
disability on general health domains such as emotional
well-being, social functioning and daily visual function. It
allows judgement of the extent to which eye diseases
impact anxiety, routine activities and the interaction with
family and friends [20]. Previous research demonstrated a
correlation between decreased visual function and depres-
sion development, which in turn hampers daily activity
[23]. This was identified as one main reason for the high
incidence of depressive disorders in patients with advanced
AMD, comparable to patients with life-threatening diseases
such as cancer or cerebrovascular diseases [24, 25]. In the
light of these correlations, baseline VFQ-25 scores can help
medical staff to provide patients with optimized medical
treatment and emotional attention.
In the NIS OCEAN, 84 % of the large patient popula-
tion performed the VFQ-25 at baseline and, thus, the re-
sults likely reflect the true situation in routine clinical
care. In general, patients might be afraid of reporting
their significantly reduced QoL and major disease bur-
den to the examining and treating medical staff, espe-
cially at a higher age [26]. However, this is important
information for judging patients’ mental strain, for pro-
viding psychological support and for increasing compli-
ance, which will result in better visual outcomes and,
consequently, in an improved QoL [23] during and after
intraocular anti-VEGF treatment.
Previous reports evaluated the impact of treatment
outcomes of better-seeing (BSE) and worse-seeing eyes
(WSE) on VFQ-25 results. It was shown that an im-
paired QoL is even evident if only one eye is affected by
the underlying disease, with unimpaired vision of the
BSE [27]. Thus, the WSE appears to have a noticeable
influence on QoL, contrary to the common assumption
that the BSE mostly determines QoL. However, the
“AMAs Guides to the Evaluation of Permanent Impair-
ment” weighted average gives a factor of 0.75 to the BSE
and of 0.25 to the WSE [26], stressing the importance of
the BSE [28]. Impaired vision in the WSE per se might
reduce QoL due to fears of losing vision in the BSE as
well [27]. QoL can even be affected prior to vision loss
due to a patient’s emotional reaction to diagnosis and
treatment [29]. A recent study finally demonstrated that
improvements in QoL scores were not significantly asso-
ciated with the treatment of either WSE or BSE. Only
VA improvements in the treated eye, irrespective of
WSE or BSE status, were associated with an increase in
QoL [15, 30]. Unfortunately, there is no distinction
between WSE and BSE in the OCEAN study.
The comparison of the OCEAN VFQ-25 baseline scores
with the results of former published phase III clinical trials
of intravitreal ranibizumab for the treatment of nAMD,
DME, and macular edema due to RVO is of clinical inter-
est (Additional file 1: Table S1). Baseline VFQ-25 out-
comes in MARINA/ANCHOR disclosed overall scores of
57.6/52.0 for the BSE as well as 78.3/79.4 for the WSE.
This in turn emphasizes the impact of VA reduction on
QoL in the BSE [15]. The mean OCEAN baseline score
(irrespective of the treatment of BSE or WSE) of 72.8 in
treatment-naïve nAMD patients is in between these
MARINA/ANCHOR scores but closer to the results for
the WSE. The same interrelation can be obtained for
almost all subscale scores [15]. In patients suffering from
DME, the overall VFQ-25 composite score at baseline was
about 66 (BSE: 52 to 60) in a recent exploratory post hoc
analysis of the RISE and RIDE data [16]. The correspond-
ing baseline score of 78.5 in treatment-naïve DME
patients in the OCEAN study is distinctly higher, even if
Table 3 Age distribution of OCEAN participants who gave up driving generally or mainly due to eyesight issues, by indication
Age group
Indication <30 30 - <40 40 - <50 50 - <60 60 - <70 70 - <80 80 - <90 90 - <100 ≥100
nAMD n 0 4 7 39 257 996 852 99 1
Gave up driving… [n (%)] 0 (0 %) 2 (50 %) 1 (14 %) 7 (18 %) 38 (15 %) 232 (23 %) 269 (32 %) 40 (40 %) 0 (0 %)
…mainly due to eyesight [n (%)] 0 (0 %) 1 (25 %) 1 (14 %) 4 (10 %) 20 (8 %) 112 (11 %) 110 (13 %) 11 (11 %) 0 (0 %)
DME n 1 11 31 110 172 259 63 3 0
Gave up driving… [n (%)] 0 (0 %) 2 (18 %) 4 (13 %) 23 (21 %) 40 (23 %) 55 (21 %) 18 (29 %) 1 (33 %) 0 (0 %)
…mainly due to eyesight [n (%)] 0 (0 %) 2 (18 %) 1 (3 %) 8 (7 %) 21 (12 %) 21 (8 %) 7 (11 %) 1 (33 %) 0 (0 %)
BRVO n 0 1 8 13 38 55 21 3 0
Gave up driving… [n (%)] 0 (0 %) 0 (0 %) 0 (0 %) 2 (15 %) 5 (13 %) 10 (18 %) 5 (24 %) 3 (100 %) 0 (0 %)
…mainly due to eyesight [n (%)] 0 (0 %) 0 (0 %) 0 (0 %) 1 (8 %) 3 (8 %) 3 (5 %) 1 (5 %) 1 (33 %) 0 (0 %)
CRVO n 0 1 1 11 19 32 15 1 0
Gave up driving… [n (%)] 0 (0 %) 1 (100 %) 0 (0 %) 2 (18 %) 3 (16 %) 4 (13 %) 3 (20 %) 1 (100 %) 0 (0 %)
…mainly due to eyesight [n (%)] 0 (0 %) 1 (100 %) 0 (0 %) 1 (9 %) 1 (5 %) 1 (3 %) 2 (13 %) 0 (0 %) 0 (0 %)
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compared to the composite score of 69 to 74 for the WSE
in RISE/RIDE [16]. This correlation is seen for almost all
subscale scores, especially for social function, mental
health and dependency [16]. Patients with macular edema
due to RVO (CRVO or BRVO) showed baseline VFQ-25
composite scores of between 76 and 77 in the BRAVO/
CRUISE trials [17]. In OCEAN, the analogous scores are
slightly higher with 79.9 to 82.5 points. Comparable
results are seen for most subscale scores, while depend-
ency, mental health and role limitations have notably
higher scores in OCEAN.
In summary, these data show that VFQ-25 composite
scores and especially emotional well-being as well as social
functioning subscale scores (e.g. social functioning, mental
health, role limitations and dependency) have increased
from the initial phase III clinical trials of intravitreally
applied anti-VEGF substances to today’s routine clinical
care. This could on the one hand reflect the awareness
and the increased expectations of patients suffering from
neovascular eye disorders with respect to this innovative
treatment option. This is supported by the comparison of
VFQ-25 baseline scores from the OCEAN study with QoL
evaluations prior to the era of anti-VEGF therapies. For
instance, VFQ-25 scores were tremendously lower in
patients with nAMD when only PDT or macular surgery
were available [23], in patients with diabetes when focal or
grid laser treatment were the only options to treat DME
[31], as well as in RVO-affected eyes [32] when merely
laser treatment and surgery for severe cases (e.g. vitrec-
tomy in combination with radial optic neurotomy [RON]
or arterio-venous sheathotomy [AVS9] [33]) were avail-
able. Thus, intravitreally injected anti-VEGF substances
have, besides anatomic and functional considerations, a
major impact on social and mental aspect and can
distinctly increase patient QoL. On the other hand, these
increased VFQ-25 composite and subscale scores herein
might be attributed to a better baseline BCVA as compared
with the pivotal phase III clinical trials (Additional file 2:
Table S2).
All clinical trials mentioned above demonstrated not
only medical improvements (e.g. in BCVA, central retinal
thickness [CRT]), but also a significant increase in QoL
scores during and after anti-VEGF treatment [15–17],
further supporting the beneficial effect of intravitreally
applied anti-VEGF substances. This effect can be useful to
reduce anxieties and to encourage patients’ compliance.
As analysed herein, the OCEAN baseline VFQ-25
scores show no major differences between indications
overall. However, a tendency towards a more decreased
visual function for nAMD in comparison to DME and
RVO patients is noted. As the indication per se cannot
be modified, there is almost no scope for QoL improve-
ment in this respect. Especially nAMD patients with
severe bilateral affection have serious difficulties in
performing most vision-dependent daily activities (e.g.
reading, seeing well close up and navigating around their
homes and neighbourhoods) due to loss of central vision
[5]. This causes distinctly low subscale scores for
dependency, role limitations, mental health and social
function, all of which demonstrate the potential isolating
effect of bilateral severe AMD [5]. Considering this,
medical staff should encourage patients to demand
psychological support, if needed, or to attend meetings
of specialized support groups, for instance. Patients
suffering from DME showed comparable scores to
nAMD patients, but a significantly worse VFQ-25 com-
posite score in comparison to glaucoma or cataract
patients and in comparison to a healthy reference group
[20]. Furthermore, DME-affected type II diabetics were
significantly more affected overall than type I diabetics
[20]. The severity of peripheral retinal alterations (diabetic
retinopathy, DR) showed an immediate impact on QoL
scores. Especially the progression from unilateral to bilat-
eral non-proliferative diabetic retinopathy (NPDR) caused
most substantial decreases [34]. If DR progresses to the
proliferative variant (PDR), a patient can lose 25 to 30
VFQ-25 points in comparison to NPDR patients, especially
in the “mental health” category [26]. Finally, lower VFQ-25
scores were independently associated with poorer VA, older
age and a history of loss of tactile sensation as a marker of
advanced systemic diabetic alterations [35]. Another publi-
cation demonstrated that, in eyes with BRVO, QoL was sig-
nificantly less affected than in nAMD and DME eyes. This
difference was attributed to the one-sided event in RVO;
whereas diabetic changes and nAMD most frequently
occur on both sides during the course of disease [36].
With respect to the impact of patients’ age on QoL, no
major differences are found between the age groups in
OCEAN. There is a tendency towards decreased visual
function with increasing age, particularly in patients
75 years or older. This observation is supported by previ-
ous investigations [1, 5], demonstrating a significant age-
dependency of VFQ-25 scores by approximately 1.0 point
for every life decade [1]. In patients suffering from severe
bilateral AMD, QoL tended to correlate negatively with in-
creasing patient age and duration of vision loss, especially
for quality of vision and vision-related QoL subscales [5].
Depression might occur more frequently in older patients
and it was formerly demonstrated that depression interferes
with VFQ-25 scores, irrespective of VA impairment [37].
This is of importance because the proportion of older
patients will increase in the future [38].
In OCEAN, no major differences between VFQ-25
scores by gender are detected. A tendency towards a more
decreased visual function for females is observed. How-
ever, in the OCEAN study, females are older than males
(≥75 years: 748 [50 %] males, 1179 [61.9 %] females at
baseline) and this age difference might be reflected in the
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gender difference. Other investigations reported better
VFQ-25 scores in females than in males [39].
With regard to the impact of baseline BCVA on VFQ-
25 scores, no major differences between groups are de-
tected in OCEAN. There is a tendency towards a more
decreased visual function for patients with a lower base-
line VA. This observation is in accordance with former
findings describing a major impact of BCVA on QoL
[19, 30, 35, 40, 41]. A summary of the mean baseline
BCVA values in OCEAN and selected clinical trials is
provided in Additional file 2: Table S2. As BCVA at the
beginning of any therapy might only be influenced mar-
ginally by the medical staff involved, attention should be
shifted towards the following intervention period.
Former investigations demonstrated that in all neovascu-
lar diseases discussed herein, BCVA increased signifi-
cantly during anti-VEGF treatment [42–46], along with
significant improvements in VFQ-25 scores [15–17, 19,
40, 47, 48]. This in turn can nourish patients’ hope that
the impaired BCVA (and QoL) will improve further.
Treatment outcomes are often less good in routine clinical
care than in phase III clinical trials because the treatment
population is more diverse and treatment tends to be less
intense [19, 30, 40, 49]. Nevertheless, a strict anti-VEGF
treatment, possibly including a treat-and-extend strategy
[41, 50], has the potential to significantly increase the
medical and mental condition of patients, to reduce
anxiety, prevent depression development and to support
therapeutic compliance. An analysis of the VFQ-25
changes in OCEAN during and after the treatment period,
in relation to therapeutic success, will be reported separ-
ately after completion of the ongoing study.
Overall, no major differences of VFQ-25 scores are
detected in OCEAN with respect to the type of health
insurance (private versus statutory health insurance).
However, there is a tendency towards a more decreased
visual function for statutorily insured patients. This is of
interest because the type of health insurance might have
an impact on QoL scores due to patients’ expectations
to receive better medical care in private health insur-
ance. However, this could not be demonstrated herein
and is only addressable to some extent.
The ANOVA analysis shows that, besides age and gen-
der, the eye-specific contributing factors (indication,
baseline VA, interactions of age and indication as well as
baseline VA and indication) have a significant impact on
the composite as well as on general and distance vision
subscale scores. Especially the general and distance
vision scores, as assessed by an ophthalmologist, are of
fundamental importance for patients’ ability to drive.
VFQ-25 and driving
In Germany the numbers of driving licences, vehicle reg-
istrations and driven kilometres decrease steadily with
age from 45 years of age on, with a distinctive reduction
from 65 years on [21, 22]. This is in line with the results
of the baseline evaluation of treatment-naïve subjects
who gave up driving as evaluated with the VFQ-25 ques-
tionnaire in the ongoing OCEAN study. Here, while
10 % of (treatment-naïve) participants in the age group
of 40 to <50 years gave up driving, the percentage in-
creases steadily with age, to 41 % in the 90 to <100 years
age group (age groups below 40 and above 100 years are
not discussed due to the low numbers of patients).
Remarkably, the percentage of patients who attributed
their giving up driving mainly to eyesight issues does not
increase as much with age. Here, the question arises
which other reasons beside eyesight are responsible for
giving up driving. Unfortunately, the VFQ-25 question-
naire does not address this issue. Therefore, it seems to
be essential that future studies evaluating QoL should
focus on this unanswered question. The discrepancy
between the overall increasing percentage of subjects
who gave up driving and the less increasing percentage of
patients relating this mainly to eyesight issues remains un-
explained. An increasing percentage of eyesight reasons
alongside with an increasing overall percentage would
have been expected. By speculation, older patients might
be or might feel adjusted to a reduced BCVA and thus do
not realize the need to stop driving. This should be a
reminder for treating ophthalmologists that they are
obliged to inform patients not to drive if they are consid-
ered unable to do so safely [51]. This seems to be of
particular importance for patients suffering from a poten-
tial bilateral neovascular eye disorder. In OCEAN, nAMD
and DME show a higher and increasing percentage of
patients who gave up driving in general than unilateral
diseases like BRVO and CRVO. Finally, the OCEAN
patients who continued driving have a considerably better
BCVA in the eye involved than those who gave up. Unfor-
tunately, BCVA measurements of the fellow eye and/or
binocular BCVA measurements are not available.
Conclusions
In summary, the analyses of the baseline VFQ-25 scores
representing patients’ QoL as reported herein show that
general health seems to be affected the most, followed by
general vision in all approved indications. Ocular pain and
colour vision seem to be least affected by the ocular
disease, followed by vision-specific social function and
vision-specific dependency. These tendencies can be seen
across all subgroup analyses. No major differences
between VFQ-25 data by predefined strata (indication,
age, gender, baseline VA and type of health insurance)
were observed. However, a significantly decreased VFQ-25
composite score was seen for the indication nAMD, for
elderly patients ≥75 years of age, for female patients, for
patients with low baseline VA (<50 letters) and for those
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with statutory health insurance. In contrast, significantly
better visual function was seen for younger (≤65 years)
patients, male patients, and patients with a baseline VA of
>65 letters or with private health insurance. The know-
ledge of a patient’s subjective disease burden is crucial to
understand the patient’s anxieties and mental anguish.
Additionally, the understanding of the impact of various
contributing factors on the VFQ-25 scores and the extent
to which they can be influenced will help to understand
each individual patient. This demonstrates the need for
medical and mental support by all medical staff to encour-
age patients’ compliance with a comprehensive anti-VEGF
therapy, because this in turn will increase BCVA and,
consecutively, QoL levels. All medical staff is required to
focus on these issues to deliver the best individual patient-
centred care before, during and after intravitreal anti-
VEGF treatment. This will increase patients’ QoL and
reduce any negative consequences of the diagnosis and
the treatment burden of intraocular anti-VEGF injections.
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